Related Experiment Video
Updated: Dec 9, 2025
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
SMAD4-Expressing Pancreatic Ductal Adenocarcinomas Have Better Response to Neoadjuvant Therapy and Significantly
Ari Kassardjian1, Hanlin L Wang
1From the Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Objective:
For many patients whose pancreatic ductal adenocarcinoma (PDAC) is locally advanced, neoadjuvant therapy has been proposed as a way to decrease tumor burden. Pancreatic ductal adenocarcinoma is generally thought to be resistant to chemotherapy and radiation, however, response to neoadjuvant therapy in PDAC has been described in a subset of patients. The SMAD4 status is considered to be an important molecular feature which distinguishes two subsets of PDAC, SMAD4-positive and -negative tumors. The objective of this study was to evaluate the neoadjuvant treatment response rate as well as compare the different clinicopathologic variables between SMAD4-positive and -negative tumors.
Methods:
We analyzed the data of patients who underwent surgical resection for PDAC from 2009-2019. Our cohort from a single institution included 233 patients.
Results:
Of the 233 cases, 143 (61.4%) were SMAD4-negative and 90 (38.6%) were SMAD4-positive. Overall, SMAD4-positive tumors with neoadjuvant therapy had better treatment response and better tumor regression scores. In addition, SMAD4-positive tumors had a significantly lower lymph node metastasis rate in both the neoadjuvant and nonneoadjuvant setting.
Conclusions:
Further characterization of the role of SMAD4 within the context of neoadjuvant therapy will lead to improved personalized therapeutic strategies.
Insights
SMAD4-positive pancreatic ductal adenocarcinoma (PDAC) shows better response to neoadjuvant therapy and less metastasis. Understanding SMAD4 status can improve personalized treatment strategies for PDAC patients.
Area of Science:
- Oncology
- Gastroenterology
- Molecular Biology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a challenging cancer, often resistant to standard treatments.
- Neoadjuvant therapy is explored to reduce tumor burden in locally advanced PDAC.
- SMAD4 gene status is a key molecular marker differentiating PDAC subtypes.
Purpose of the Study:
- To evaluate neoadjuvant treatment response rates in PDAC.
- To compare clinicopathologic variables between SMAD4-positive and SMAD4-negative PDAC tumors.
Main Methods:
- Retrospective analysis of 233 PDAC patients undergoing surgical resection (2009-2019).
- Comparison of treatment response and metastasis rates based on SMAD4 status.
Main Results:
- SMAD4-positive tumors (38.6%) demonstrated superior response and regression scores with neoadjuvant therapy compared to SMAD4-negative tumors (61.4%).
- SMAD4-positive PDAC exhibited significantly lower lymph node metastasis rates in both neoadjuvant and non-neoadjuvant settings.
Conclusions:
- SMAD4 status is a significant predictor of neoadjuvant treatment response in PDAC.
- Further research into SMAD4's role can enhance personalized therapeutic strategies for PDAC.
